SPONSOR
Beijing Biotech
Total Trials
4
Recruiting
4
Phases
Phase 1, Phase 2
Conditions studied: Breast Cancer (Locally Advanced or Metastatic)HER2-positive Breast CancerTriple-Negative Breast Cancer (TNBC)Advanced or Metastatic Clear Cell Renal Cell CarcinomaEpithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube CarcinomaRecurrent or Refractory Disease After Standard TherapiesNon-Small Cell Lung CancerAdvanced/Metastatic NSCLC
Beijing Biotech is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC), Advanced or Metastatic Clear Cell Renal Cell Carcinoma.
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Beijing Biotech
How many clinical trials has Beijing Biotech sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by Beijing Biotech, of which 4 are actively recruiting participants. These trials cover conditions including Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Beijing Biotech research focus on?
Beijing Biotech clinical trials span Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC), Advanced or Metastatic Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, and additional conditions. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Beijing Biotech clinical trial?
To participate in a Beijing Biotech trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Beijing Biotech trials with current recruitment status updated daily.
Clinical Trials by Beijing Biotech
NCT07486089 Phase 1, Phase 2
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Breast Cancer (Locally Advanced or Metastatic)
NCT07551349 Phase 1, Phase 2
Recruiting
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT07617753 Phase 1, Phase 2
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
Epithelial Ovarian Cancer
NCT07467863 Phase 1, Phase 2
Recruiting
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
Non-Small Cell Lung Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology